NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape- The global kidney stones therapeutic market size is estimated to grow by USD 537.8 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 4.96% during the forecast period. Growing popularity of flexible digital ureteroscopes is driving market growth, with a trend towards advances in technologies in kidney stones treatment.
However, decreasing number of urologists coupled with shortage of skilled surgeons poses a challenge. Key market players include Anvik Biotech, Aristo Pharma GmbH, Bausch Health Companies Inc., Bayer AG, Biomedix Siomond Pharma, Cipla Inc.
, Cmg Biotech Pvt. Ltd., Dr Reddys Laboratories Ltd.
, Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc.
, Macleods Pharmaceuticals Ltd., Medinova Diagnostic Services Ltd., Mission Pharmacal Co.
, Nostrum Pharmaceuticals LLC, Pfizer Inc., Walter Bushnell , Windlas Biotech Pvt. Ltd.
, and Worth Medicines Pvt. Ltd. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth The kidney stones therapeutic market has witnessed significant advancements in the past three decades, driven by technological innovations in kidney stones treatment procedures. Lithotripsy, URS, and percutaneous techniques have rev.